October 15th 2026, 5:06 PM
Iambic Therapeutics IPO Marks AI-Powered Cancer Drug Development Momentum
Key Summary
Iambic Therapeutics' Nasdaq debut after a $150M IPO sees the company's shares rise 16% to $18.50, marking enthusiasm from public investors in its AI-powered cancer drug development. The IPO adds to the company's private funding and raises market value between $758M and $877M.
Please see our real time news feed on our Home Page
Iambic Therapeutics IPO Overview
Iambic Therapeutics just completed its Nasdaq debut after a $150 million initial public offering. The company's shares rose 16% to $18.50 on October 15, 2026.How the Offering Came Together
Iambic priced its IPO on October 14, 2026, at $16 per share, sitting at the midpoint of its projected range. The company sold 9.375 million shares to raise the $150 million.What Iambic Actually Does
The company uses proprietary AI systems called NeuralPLexer and Enchant. It pairs these systems with automated, high-throughput chemistry and biology labs that test candidates at scale. Iambic's stated ambition is to move candidates from design into clinical trials in approximately two years. It focuses on small-molecule drugs with oncology as its main battleground.Key Backers and Financials
Iambic's backer list includes Nvidia, ARK Investment Management, and Sequoia. The company reported a net loss of $94.25 million in figures through June 30, 2026, and booked $18.25 million in collaboration revenue over that period.#Biotech#IPO#ArtificialIntelligence#CancerDrugDevelopment